Zusammenfassung
Nachweis von Codein im Harn von chronisch mit Morphin-Injektionen behandelten Personen. Diese Codein-Spuren können jedoch aus Verunreinigungen des benützten Morphins stammen und bilden daher keinen Beweis dafür, dass Codein beim Menschen durch Biotransformation als Metabolit von Morphin entsteht.
Rerefences
S. Y. Yeh, Fedn. Proc.32, 763 (1973).
U. Börner andS. Abbott, Experientia29, 180 (1973).
TLC was performed on Quantum Silica gel precoated plates, developed with ethyl acetate:methanol:ammonium hydroxide (28%) (17:2:1) and sprayed with pot. iodoplatinate reagent.
A Varian Aerograph, Series 2700, equipped with a 5 foot×2 mm stainless steel column packed with 3% SE-30 coated on Varaport 100/120 and a 3 foot×2 mm glass column packed with 3% OV-17 coated on gas-chrom Q, 60/80 mesh and flame ionization detectors. Temperatures for injector, column and detector, were 255°, 250° and 295°C, respectively.
S. Y. Yeh, Report of the 36th Annual Meeting of NAS-NRC Committee on Problems of Drug Dependence (1973), p. 215.
Five ml urine was hydrolyzed with 20% by volume of concentration HCl in a steam jacketed autoclave at 15 lb pressure for 30 min, adjusted to pH 14 with NaOH, salted with NaCl and extracted with 15 ml of CHCl3 by shaking for 15 min and centrifuged for 15 min. The aqueous phase was discarded and 13 ml of the organic phase was extracted with 2.5 ml of 2N HCl. After removal of the organic phase the acidic aqueous phase was again adjusted to pH 14 and extracted with CHCl3. 13 ml of the organic phase and 0.05 ml of cholestane (0.1 mg/ml) solution were evaporated to dryness and the residue acetylated with 0.2 ml of acetic anhydride and 0.1 ml of pyridine in a sealed tube at 60–70°C for 1 h. The excess acetic anhydride was removed and the residue dissolved in 0.05 ml ethyl acetate and 1 μl of the solution injected into the GC.
S. J. Mulé, Analyt. Chem.36, 1907 (1964).
G. R. Nakamura andT. Ukita, J. Forens. Sci.7, 465 (1962); Bulletin on Narcotics,15, 43 (1963); J. Ass. Off. analyt. Chem.49, 1086 (1966).
C. Elison andH. W. Elliott, J. Pharmac. exp. Ther.144, 265 (1964).
R. Schmid, J. Axelrod, L. Hammaker andL. Swarm, J. clin. Invest.37, 1123 (1958).
G. J. Mannering, A. C. Dixon, E. M. Baker, III andT. Asami, J. Pharmac. exp. Ther.111 142 (1954).T. K. Adler, J. M. Fujimoto, E. Leong Way andE. Baker, J. Pharmac. exp. Ther.114, 251 (1955). —P. Paerregaard, Acta pharmac. toxic.14, 394 (1958). —N. Remond andT. K. Parker, Can. J. Biochem. Physiol.41, 243 (1963). —W.O. R. Ebbinghausen. J Mowat andP. Vestergaard, J. pharmac. Sci.62, 146 (1973).
L. A. Woods, H. E. Muehlenbach andL. B. Mellet J. Pharmac. exp. Ther.117, 117 (1956).
S. Y. Yeh andL. A. Woods, J. Pharmac. exp. Ther.173, 21 (1970).
S. Y. Yeh andL. A. Woods, Archs int. Pharmacodyn Thér.191, 231 (1971).
T. K. Adler andM. E. Latham, Proc. Soc. exp. Biol. Med.73, 401 (1950). —T. K. Adler andF. H. Shaw, J. Pharmac. exptl. Ther.104, 1 (1952). —H.-F. Kuhn andH. Friebel, Med. exp.7, 255 (1962). —S. Y. Yeh andL. A. Woods, J. Pharmac exp. Ther.166. 86 (1969);S. Y. Yeh andL. A. Woods, J. Pharmac. exp. Ther.175, 69 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yeh, S.Y. Absence of evidence of biotransformation of morphine to codeine in man. Experientia 30, 264–266 (1974). https://doi.org/10.1007/BF01934818
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01934818